(Total Views: 318)
Posted On: 08/21/2024 2:22:42 PM
Post# of 36541
Youfeng Bio website Ii-key
Ii-Key Peptide Technology Platform
Ii-Key peptide technology platform
Platform Introduction
——
The innovative Ii-Key peptide technology has a history of more than 30 years of research and development. It mainly targets T cell immunity and overcomes industry problems such as easy degradation and weak immunogenicity of peptides in the body, making this peptide technology a reliable technology platform for the pharmaceutical and vaccine industries. At the same time, Ii-Key technology has also changed the past T cell immune activation mechanism and pioneered in vivo targeted T cell immunity technology.
Based on this platform, more than 10 patents have been registered, and more than 20 product pipelines have been laid out in the field of infectious diseases and tumors. Among them, the AE37 vaccine has completed the Phase IIb clinical triple-negative breast cancer combination drug trial in the United States, GP2 has completed the Phase II clinical trial of HER2-positive breast cancer, prostate cancer and bladder cancer vaccines have completed Phase IIa clinical trials, and swine flu, avian flu and melanoma vaccines have completed Phase I clinical trials in the United States; RSV, HPV, and HIV vaccines have been carried out in preclinical research, and research data show that the products have high clinical research value; the new crown vaccine has been approved for clinical trials in Nigeria and clinical ethics approval in Brazil. In summary, the clinical trial data show that the Ii-Key peptide vaccine is very safe, and no side effects above grade 2 have occurred.
National project
• In March and November 2021, the Institute of Viral Disease Prevention and Control of the Chinese Center for Disease Control and Prevention reported the Ii-Key peptide COVID-19 vaccine as the national "second-generation universal COVID-19 vaccine" to the Joint Prevention and Control Mechanism of the State Council
• In July 2022, the 2022 Science and Technology Anti-epidemic International Cooperation Targeted Project of the National 14th Five-Year Key R&D Program "Strategic Science and Technology Innovation Cooperation" key project was approved
• In December 2022, the National 14th Five-Year Key R&D Program Pathogens and Epidemic Prevention Technology System Research Special Project "Research on the New Coronavirus Preventive Nasal Spray Ii-Key Peptide Vaccine" Young Scientist Project was approved
Technical principle
——
The innovative Ii-Key peptide technology has a history of more than 30 years of research and development. It mainly targets T cell immunity and overcomes industry problems such as easy degradation and weak immunogenicity of peptides in the body, making this peptide technology a reliable technology platform for the pharmaceutical and vaccine industries. At the same time, Ii-Key technology has also changed the past T cell immune activation mechanism and pioneered in vivo targeted T cell immunity technology.
Based on this platform, more than 10 patents have been registered, and more than 20 product pipelines have been laid out in the field of infectious diseases and tumors. Among them, the AE37 vaccine has completed the Phase IIb clinical triple-negative breast cancer combination drug trial in the United States, GP2 has completed the Phase II clinical trial of HER2-positive breast cancer, prostate cancer and bladder cancer vaccines have completed Phase IIa clinical trials, and swine flu, avian flu and melanoma vaccines have completed Phase I clinical trials in the United States; RSV, HPV, and HIV vaccines have been preclinical studies, and research data show that the products have high clinical research value; the new crown vaccine has been approved for clinical trials in Nigeria and clinical ethics approval in Brazil. In summary, the clinical trial data show that the Ii-Key peptide vaccine is very safe, and no side effects above grade 2 have occurred.
https://www.google.com/url?sa=t&source=we...Ud_Y4eCTsg
Ii-Key Peptide Technology Platform
Ii-Key peptide technology platform
Platform Introduction
——
The innovative Ii-Key peptide technology has a history of more than 30 years of research and development. It mainly targets T cell immunity and overcomes industry problems such as easy degradation and weak immunogenicity of peptides in the body, making this peptide technology a reliable technology platform for the pharmaceutical and vaccine industries. At the same time, Ii-Key technology has also changed the past T cell immune activation mechanism and pioneered in vivo targeted T cell immunity technology.
Based on this platform, more than 10 patents have been registered, and more than 20 product pipelines have been laid out in the field of infectious diseases and tumors. Among them, the AE37 vaccine has completed the Phase IIb clinical triple-negative breast cancer combination drug trial in the United States, GP2 has completed the Phase II clinical trial of HER2-positive breast cancer, prostate cancer and bladder cancer vaccines have completed Phase IIa clinical trials, and swine flu, avian flu and melanoma vaccines have completed Phase I clinical trials in the United States; RSV, HPV, and HIV vaccines have been carried out in preclinical research, and research data show that the products have high clinical research value; the new crown vaccine has been approved for clinical trials in Nigeria and clinical ethics approval in Brazil. In summary, the clinical trial data show that the Ii-Key peptide vaccine is very safe, and no side effects above grade 2 have occurred.
National project
• In March and November 2021, the Institute of Viral Disease Prevention and Control of the Chinese Center for Disease Control and Prevention reported the Ii-Key peptide COVID-19 vaccine as the national "second-generation universal COVID-19 vaccine" to the Joint Prevention and Control Mechanism of the State Council
• In July 2022, the 2022 Science and Technology Anti-epidemic International Cooperation Targeted Project of the National 14th Five-Year Key R&D Program "Strategic Science and Technology Innovation Cooperation" key project was approved
• In December 2022, the National 14th Five-Year Key R&D Program Pathogens and Epidemic Prevention Technology System Research Special Project "Research on the New Coronavirus Preventive Nasal Spray Ii-Key Peptide Vaccine" Young Scientist Project was approved
Technical principle
——
The innovative Ii-Key peptide technology has a history of more than 30 years of research and development. It mainly targets T cell immunity and overcomes industry problems such as easy degradation and weak immunogenicity of peptides in the body, making this peptide technology a reliable technology platform for the pharmaceutical and vaccine industries. At the same time, Ii-Key technology has also changed the past T cell immune activation mechanism and pioneered in vivo targeted T cell immunity technology.
Based on this platform, more than 10 patents have been registered, and more than 20 product pipelines have been laid out in the field of infectious diseases and tumors. Among them, the AE37 vaccine has completed the Phase IIb clinical triple-negative breast cancer combination drug trial in the United States, GP2 has completed the Phase II clinical trial of HER2-positive breast cancer, prostate cancer and bladder cancer vaccines have completed Phase IIa clinical trials, and swine flu, avian flu and melanoma vaccines have completed Phase I clinical trials in the United States; RSV, HPV, and HIV vaccines have been preclinical studies, and research data show that the products have high clinical research value; the new crown vaccine has been approved for clinical trials in Nigeria and clinical ethics approval in Brazil. In summary, the clinical trial data show that the Ii-Key peptide vaccine is very safe, and no side effects above grade 2 have occurred.
https://www.google.com/url?sa=t&source=we...Ud_Y4eCTsg
(2)
(0)Scroll down for more posts ▼
